Abstract
Curcumin, a dietary phytochemical, exhibits multifunctional natural product with regulatory effects on inflammation. However, its poor bioavailability limits its clinical applications. Thus, we designed and synthesized a novel monocarbonyl analogue of curcumin B7 and their inhibition against monocyte chemotactic protein-1 (MCP-1) and Interleukin-8 (IL-8) release was evaluated in H2O2-stimulated human vascular endothelial cells (ECs) in a dose-responsive manner, while exhibiting no cytotoxicity in ECs. Taken together, these insights on the novel compound B7 may serve as potential agents for the treatment of atherosclerosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Wei, D., Liu, Y., Jia, X., Guo, F., Wu, J. (2013). A novel synthetic analogue of curcumin, B7, inhibits inflammatory factors expression in H2O2 induced endothelial cells. In: Long, M. (eds) World Congress on Medical Physics and Biomedical Engineering May 26-31, 2012, Beijing, China. IFMBE Proceedings, vol 39. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29305-4_166
Download citation
DOI: https://doi.org/10.1007/978-3-642-29305-4_166
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-29304-7
Online ISBN: 978-3-642-29305-4
eBook Packages: EngineeringEngineering (R0)